AR038985A1 - Parecoxib sodico cristalino - Google Patents
Parecoxib sodico cristalinoInfo
- Publication number
- AR038985A1 AR038985A1 ARP030100915A ARP030100915A AR038985A1 AR 038985 A1 AR038985 A1 AR 038985A1 AR P030100915 A ARP030100915 A AR P030100915A AR P030100915 A ARP030100915 A AR P030100915A AR 038985 A1 AR038985 A1 AR 038985A1
- Authority
- AR
- Argentina
- Prior art keywords
- solvated
- parecoxib
- parecoxib sodium
- drug substance
- sodico
- Prior art date
Links
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 title 1
- 229960004662 parecoxib Drugs 0.000 title 1
- 229960003925 parecoxib sodium Drugs 0.000 abstract 3
- ICJGKYTXBRDUMV-UHFFFAOYSA-N trichloro(6-trichlorosilylhexyl)silane Chemical compound Cl[Si](Cl)(Cl)CCCCCC[Si](Cl)(Cl)Cl ICJGKYTXBRDUMV-UHFFFAOYSA-N 0.000 abstract 3
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 2
- 229940088679 drug related substance Drugs 0.000 abstract 2
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 230000001754 anti-pyretic effect Effects 0.000 abstract 1
- 239000002221 antipyretic Substances 0.000 abstract 1
- 239000012736 aqueous medium Substances 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 238000004108 freeze drying Methods 0.000 abstract 1
- 239000007972 injectable composition Substances 0.000 abstract 1
- 230000036407 pain Effects 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
- C07D457/06—Lysergic acid amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36456702P | 2002-03-15 | 2002-03-15 | |
| US41798702P | 2002-10-11 | 2002-10-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR038985A1 true AR038985A1 (es) | 2005-02-02 |
Family
ID=28045416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030100915A AR038985A1 (es) | 2002-03-15 | 2003-03-14 | Parecoxib sodico cristalino |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20030232871A1 (enExample) |
| EP (1) | EP1485362A1 (enExample) |
| JP (1) | JP2005529084A (enExample) |
| KR (1) | KR100763045B1 (enExample) |
| CN (1) | CN1642926A (enExample) |
| AR (1) | AR038985A1 (enExample) |
| AU (1) | AU2003220180A1 (enExample) |
| BR (1) | BR0308431A (enExample) |
| CA (1) | CA2478500A1 (enExample) |
| CO (1) | CO5631437A2 (enExample) |
| IL (1) | IL163780A0 (enExample) |
| MX (1) | MXPA04008932A (enExample) |
| MY (1) | MY148518A (enExample) |
| NZ (1) | NZ535951A (enExample) |
| PL (1) | PL372880A1 (enExample) |
| RU (1) | RU2300529C2 (enExample) |
| TW (1) | TW200400949A (enExample) |
| WO (1) | WO2003078408A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050143431A1 (en) * | 2003-04-04 | 2005-06-30 | Hetero Drugs Limited | Novel crystalline forms of parecoxib sodium |
| JP2007507538A (ja) | 2003-10-02 | 2007-03-29 | エラン ファーマシューティカルズ，インコーポレイテッド | 疼痛軽減方法 |
| JP2007517013A (ja) * | 2003-12-24 | 2007-06-28 | ファルマシア コーポレーション | 炎症、疼痛および／または発熱の治療を目的としたｃｏｘ−２阻害薬バルデコキシブのプロドラッグとしてのパレコキシブ金属塩 |
| ITMI20040019A1 (it) * | 2004-01-12 | 2004-04-12 | Univ Bari | Derivati isossazolici e loro impiego come inibitori della ciclossigenasi |
| US7796785B2 (en) * | 2005-03-03 | 2010-09-14 | Fujifilm Corporation | Image extracting apparatus, image extracting method, and image extracting program |
| US20080108664A1 (en) * | 2005-12-23 | 2008-05-08 | Liu Belle B | Solid-state form of AMG 706 and pharmaceutical compositions thereof |
| US7989450B2 (en) | 2008-01-11 | 2011-08-02 | Universita' Degli Studi Di Bari | Functionalized diarylisoxazoles inhibitors of ciclooxygenase |
| GB0919757D0 (en) * | 2009-11-12 | 2009-12-30 | Johnson Matthey Plc | Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs |
| US8299295B2 (en) | 2009-10-15 | 2012-10-30 | Johnson Matthey Public Limited Company | Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs |
| CN105726496B (zh) * | 2014-12-12 | 2019-05-28 | 湖南科伦药物研究有限公司 | 一种帕瑞昔布钠冻干粉剂、其制备方法及其粉剂产品 |
| CN105125506A (zh) * | 2015-08-18 | 2015-12-09 | 上海秀新臣邦医药科技有限公司 | 一种注射用帕瑞昔布钠及其制备方法 |
| CN106580893A (zh) * | 2016-12-26 | 2017-04-26 | 上药东英（江苏）药业有限公司 | 一种帕瑞昔布钠冻干粉针制剂 |
| CN106692079A (zh) * | 2016-12-26 | 2017-05-24 | 上药东英（江苏）药业有限公司 | 一种帕瑞昔布钠长效冻干粉针制剂 |
| CN117003769B (zh) * | 2023-07-11 | 2024-11-22 | 中国科学院宁波材料技术与工程研究所 | 氯诺昔康复合物、氯诺昔康-小檗碱共晶及其制备方法和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1288206B1 (en) * | 1996-04-12 | 2008-09-17 | G.D. Searle LLC | Substituted benzenesulfonamide derivatives as prodrugs of COX-2 inhibitors |
| CN100558356C (zh) * | 1996-10-15 | 2009-11-11 | G.D.瑟尔公司 | 应用环加氧酶-2抑制剂治疗和预防肿瘤形成的方法 |
| PE20021017A1 (es) * | 2001-04-03 | 2002-11-24 | Pharmacia Corp | Composicion parenteral reconstituible |
| IL161086A0 (en) * | 2001-10-02 | 2004-08-31 | Pharmacia Corp | Method for preparing benzenesulfonyl compounds |
-
2003
- 2003-03-12 KR KR1020047014454A patent/KR100763045B1/ko not_active Expired - Fee Related
- 2003-03-12 CN CNA038060884A patent/CN1642926A/zh active Pending
- 2003-03-12 RU RU2004127585/04A patent/RU2300529C2/ru not_active IP Right Cessation
- 2003-03-12 WO PCT/US2003/007484 patent/WO2003078408A1/en not_active Ceased
- 2003-03-12 MX MXPA04008932A patent/MXPA04008932A/es unknown
- 2003-03-12 JP JP2003576414A patent/JP2005529084A/ja active Pending
- 2003-03-12 PL PL03372880A patent/PL372880A1/xx not_active Application Discontinuation
- 2003-03-12 EP EP03716476A patent/EP1485362A1/en not_active Withdrawn
- 2003-03-12 CA CA002478500A patent/CA2478500A1/en not_active Abandoned
- 2003-03-12 BR BR0308431-0A patent/BR0308431A/pt not_active IP Right Cessation
- 2003-03-12 US US10/387,173 patent/US20030232871A1/en not_active Abandoned
- 2003-03-12 IL IL16378003A patent/IL163780A0/xx unknown
- 2003-03-12 AU AU2003220180A patent/AU2003220180A1/en not_active Abandoned
- 2003-03-12 NZ NZ535951A patent/NZ535951A/en unknown
- 2003-03-14 TW TW092105693A patent/TW200400949A/zh unknown
- 2003-03-14 MY MYPI20030900A patent/MY148518A/en unknown
- 2003-03-14 AR ARP030100915A patent/AR038985A1/es unknown
-
2004
- 2004-09-10 CO CO04090186A patent/CO5631437A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PL372880A1 (en) | 2005-08-08 |
| JP2005529084A (ja) | 2005-09-29 |
| RU2300529C2 (ru) | 2007-06-10 |
| EP1485362A1 (en) | 2004-12-15 |
| KR100763045B1 (ko) | 2007-10-04 |
| CA2478500A1 (en) | 2003-09-25 |
| KR20040095288A (ko) | 2004-11-12 |
| CO5631437A2 (es) | 2006-04-28 |
| RU2004127585A (ru) | 2005-04-10 |
| MXPA04008932A (es) | 2004-11-26 |
| US20030232871A1 (en) | 2003-12-18 |
| AU2003220180A1 (en) | 2003-09-29 |
| NZ535951A (en) | 2006-02-24 |
| CN1642926A (zh) | 2005-07-20 |
| IL163780A0 (en) | 2005-12-18 |
| WO2003078408A1 (en) | 2003-09-25 |
| MY148518A (en) | 2013-04-30 |
| BR0308431A (pt) | 2005-01-18 |
| TW200400949A (en) | 2004-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR038985A1 (es) | Parecoxib sodico cristalino | |
| SV2002000195A (es) | Compuestos farmaceuticamente activos ref. pcs10342 afae/bb | |
| BR0014869A (pt) | Composição e método para estabilização da mesma | |
| AR045937A1 (es) | Modulacion de la expresion del factor de iniciacion eucariotico eif4e | |
| ES2162517T3 (es) | Composicion farmaceutica que comprende una combinacion de metformin y fibrato y su uso en la preparacion de medicamentos destinados a reducir la hiperglicemia. | |
| EA200200619A1 (ru) | Непептидильные ингибиторы vla-4-зависимого связывания клеток, применяемые при лечении воспалительных, аутоимунных и респираторных заболеваний | |
| AR020788A1 (es) | Una composicion en barra extruida con poco o nada de tensioactivo sintetico | |
| LU93066I2 (fr) | Combinaison de a) olodatérol, isomèrers optiques individuels de celui-ci, melanges d'énantionmères indiviou de recémates, leurs sels d'addition d'acide avec des acides pharmaceutiquement acceptables, éventuellement sous forme de solvates et/ou hycrates, et b.) un sel de tiotropium ; en particulier une combinaison de a) olodatérol et sis sels d'addition d'acide avec des acides pharmaceutiquement acceptables et b.) du bromure de tiotropium, éventuellement sous forme de solvate et/ou hydrate , plus particulièrement une combinaison de a) hadrochlorure d'olodatérol et b.) de bromure de tiotropium, éventuellement sous forme de monohydrate | |
| ECSP034444A (es) | Derivados de 4-amino-6-fenil-pirrolo(2,3-d)pirimidina | |
| AR049590A1 (es) | Composiciones de limpieza humectantes suaves | |
| ES2192101T3 (es) | Formas cristalinas de eto2c-ch2-(r)cgl-aze-pab-oh. | |
| NI200800169A (es) | Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor | |
| CO4810375A1 (es) | Derivados de 9-amino-3-ceto eritromicina | |
| ES2123721T3 (es) | Formulaciones de rapamicina para inyecciones por via intravenosa. | |
| PA8542901A1 (es) | Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple | |
| ES2193233T3 (es) | Uso de amiodipina, una sal de la misma o felodipina en combinacion con un inhibidor ace en la fabricacion de un medicamento para el tratamiento de insuficiencia cardiaca conjuntiva no isquemica. | |
| AR018706A1 (es) | Uso de una composicion farmaceutica para tratamiento de infecciones virales | |
| MXPA02012730A (es) | Uso de acido pamoico o uno de sus derivados o uno de sus analogos para la preparacion de un medicamento para el tratamiento de enfermedades caracterizadas por depositos de agregados de amiloide. | |
| ES2129448T3 (es) | Uso de 2-(2-nitro-4-trifluorometilbenzoil)-1,3-ciclohexanodiona en el tratamiento de tirosinemia y composiciones farmaceuticas. | |
| AR007052A1 (es) | Un derivado de carbohidrato, su uso y una composicion farmaceutica que lo comprende | |
| UY27074A1 (es) | Derivados de aminotriazolopiridina | |
| UY28535A1 (es) | Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos. | |
| GT200000224A (es) | Composicion para el tratamiento de tejidos dañados. | |
| EA200201232A1 (ru) | Производные сульфонамида | |
| BR0108727A (pt) | Composição micelar para o tratamento de doenças parasìticas em animais, e, uso de uma composição |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |